PREcision meDICine in Treatment in CardioVascular Disease (NCT07369141) | Clinical Trial Compass
WithdrawnNot Applicable
PREcision meDICine in Treatment in CardioVascular Disease
Stopped: Despite extensive modelling, it was not possible to develop a model that had sufficient accuracy and could be readily applied in a clinical trial.
Netherlands0Started 2026-02
Plain-language summary
The main goal of PREDICT-CVS is to demonstrate that a personalized, AI-derived biomarker-guided medication treatment algorithm that provides advice to the treating professional is superior to prevent clinical events and improve quality of life (QoL) when compared to patients receiving standard treatment of care.
Participants will be randomized into two groups
* Group 1 - Standard treatment Participant will receive the usual treatment for heart failure, based on current medical guidelines.
* Group 2 - AI-supported treatment The professional will receive a personalized treatment plan generated by the AI program. This plan is based on medical information and biomarkers. The professional can choose whether or not to follow the AI's advice, reasons for not following the AI-based advice will be collected.
Participants will visit the outpatient clinic at 1, 2, 3 and 9 months after being randomized.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Provide written and dated informed consent for participation prior to trial admission,
✓. Age ≥18 years, female or male
✓. Diagnosis of heart failure\* either before discharge of a heart failure hospital admission or in the outpatient setting,
✓. Symptomatic, defined as NYHA class II - IV,
✓. LVEF \< 50% measured in the last 12 months (using any modality), with no occurrence of HF event(s) since that measurement) and
✓. Those not previously treated with evidence-based therapies or sub-optimally treated with GDMT defined as; • Not treated with one of the foundational four\*\* HF medication unless absolute contraindication or documented intolerance
Exclusion criteria
✕. Inability to understand and sign informed consent,
✕. Scheduled or on renal replacement therapy,
✕. Clearly documented intolerance to BBs, ARNI, SGLT2i or MRAs